Why the study?
Nitroglycerin used for therapeutic hypotension in cardiac surgery can cause adverse responses like decreased stroke volume, cardiac output, organ perfusion, and tolerance, necessitating safe and effective alternatives.
Does clevidipine provide an effective and safe alternative to intravenous nitroglycerin for therapeutic hypotension in patients undergoing cardiac surgery?
Does clevidipine provide an effective and safe alternative to intravenous nitroglycerin for therapeutic hypotension in patients undergoing cardiac surgery?
Clevidipine is a safe and effective alternative to nitroglycerin for managing therapeutic hypotension during cardiac surgery.
May support clevidipine for intraoperative hypotension in cardiac surgery; leaves open confirmation in randomized trials.
Cardiac surgery requires periods of therapeutic hypotension. Anesthesia providers often administer intravenous (IV) nitroglycerin to accomplish these meticulous hemodynamic goals. However, patients occasionally manifest adverse responses to nitroglycerin such as decreased stroke volume (SV), decreased cardiac output (CO), decreased renal, splanchnic, cerebral perfusion, and tolerance. In these situations, an alternative medication is needed that is just as effective and safe for the patient. Clevidipine is currently the best choice for this because it has rapid onset and termination of action, and it has arterial specific effects. Multiple studies show that clevidipine is as effective and safe as nitroglycerin.
No takes yet. Share an insight, caveat, or question.
Harville et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: